BC133 is effective against CD33⁺AML in lymphoma models. (A) Female NSG mice were implanted subcutaneously with 3 million MOLM13 AML cells. PBMCs (10 million-30 million per dose) were injected once per week for 4 weeks starting at 7 days after leukemia injection. BC133 (50 μg per dose for the first 3 weeks and 150 μg per dose for the remaining time) were injected 1 day before and 1 day after each PBMC administration. No IL-2 was given to the mice. (B-C) Female NSG mice were implanted subcutaneously with 2 million THP1 cells (B) or 1 million HL60 AML cells (C). PBMCs (10 million per dose) were injected once per week for 4 weeks starting at 7 days after leukemia injection. BC133 (100 μg per dose) was injected 1 day before and 1 day after each PBMC administration. No IL-2 was given to the mice.